MBOT Microbot Medical
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Company profile
Ticker
MBOT
Exchange
Website
CEO
Harel Gadot
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Seagen ...
Former names
CYTOTHERAPEUTICS INC/DE, STEMCELLS INC
SEC CIK
Corporate docs
IRS number
943078125
MBOT stock data
()
Investment data
Securities sold
Number of investors
Calendar
17 May 21
13 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 17.92M | 17.92M | 17.92M | 17.92M | 17.92M | 17.92M |
| Cash burn (monthly) | 575.33K | 971.75K | 797.33K | 776.5K | 664.67K | 575K |
| Cash used (since last report) | 1.41M | 2.39M | 1.96M | 1.91M | 1.63M | 1.41M |
| Cash remaining | 16.51M | 15.54M | 15.97M | 16.02M | 16.29M | 16.51M |
| Runway (months of cash) | 28.7 | 16.0 | 20.0 | 20.6 | 24.5 | 28.7 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Feb 21 | Gadot Harel | Stock Option Common Stock, par value $0.01 per share | Grant | Aquire A | No | No | 8.48 | 190,000 | 1.61M | 190,000 |
| 5 Nov 20 | Prattipati Laxminarain | Stock Option Common Stock, par value $0.01 per share | Grant | Aquire A | No | No | 7.22 | 2,771 | 20.01K | 2,771 |
| 5 Nov 20 | Scott R Burell | Stock Option Common Stock, par value $0.01 per share | Grant | Aquire A | No | No | 7.22 | 2,771 | 20.01K | 2,771 |
| 5 Nov 20 | Bornstein Yoseph | Stock Option Common Stock, par value $0.01 per share | Grant | Aquire A | No | No | 7.22 | 2,771 | 20.01K | 2,771 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology.
- In light of these risks and uncertainties, and especially given the nature of our existing and proposed business, there can be no assurance that the forward-looking statements contained in this section and elsewhere in this Quarterly Report on Form 10-Q will in fact occur. Potential investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
bond, Circuit, Civil, Clerk, denial, denied, enforce, failure, firm, fourth, freeze, Integra, Judgement, loan, nil, opposition, payroll, permission, post, prejudice, purportedly, Recommendation, recommended, registered, satisfy, settle, submission, writ
Removed:
accredited, adjustment, agent, annum, approved, arrangement, arrived, assessing, awarded, belong, borrow, borrowing, capitalized, classification, closing, collaborating, collateralized, comprehensive, consumed, contractual, copyrightable, cover, deducting, defend, deficit, determination, direct, disclose, distribution, divest, earliest, economic, efficacy, eligible, employee, entity, environment, equal, exercisable, exercised, expensed, free, functional, implicit, Incentive, indexed, institutional, intrinsic, irrevocable, joint, jointly, July, longer, lose, merit, modified, multiplied, negotiate, negotiated, nonrecurring, Nonrefundable, office, patentable, perpetual, phase, placement, practice, preliminary, prepaid, prepayment, present, protection, receive, recently, restated, resulted, retrospective, Reverse, reviewing, round, SCSTM, setting, site, specific, split, terminate, timing, title, typically, underwriter, uneven, university, unrecognized, unvested, updated, valuation, vendor, vigorously, Washington, Wayne, workplan, WSU
Financial reports
10-Q
2021 Q1
Quarterly report
17 May 21
10-K/A
2020 FY
Annual report (amended)
14 Apr 21
10-K
2020 FY
Annual report
31 Mar 21
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
14 Apr 20
NT 10-K
Notice of late annual filing
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
Current reports
8-K
Entry into a Material Definitive Agreement
10 Jun 21
8-K
Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board
7 Jun 21
8-K
Microbot Medical Secures Additional Protection for the One and Done Guidewire Technology with another Notice of Patent Allowance
4 Jun 21
8-K
Material Modifications to Rights of Security Holders
3 May 21
8-K
Departure of Directors or Certain Officers
22 Apr 21
8-K
Departure of Directors or Certain Officers
7 Apr 21
8-K
Regulation FD Disclosure
9 Mar 21
8-K
Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology
4 Feb 21
8-K
Microbot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt
27 Jan 21
8-K
Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
21 Jan 21
Registration and prospectus
424B5
Prospectus supplement for primary offering
10 Jun 21
S-3
Shelf registration
25 Nov 20
S-8
Registration of securities for employees
25 Nov 20
D
Indefinite amount in options / securities to be acquired, 1 investor
7 Jan 20
D
Indefinite amount in options / securities to be acquired, 1 investor
7 Jan 20
D
Indefinite amount in options / securities to be acquired, 1 investor
7 Jan 20
424B5
Prospectus supplement for primary offering
31 Dec 19
424B5
Prospectus supplement for primary offering
30 Dec 19
424B5
Prospectus supplement for primary offering
27 Dec 19
RW
Registration withdrawal request
12 Dec 19
Proxies
DEF 14A
Definitive proxy
31 Jul 20
DEF 14A
Definitive proxy
9 Aug 19
PRE 14A
Preliminary proxy
29 Jul 19
DEFR14A
Revised proxy
27 Jul 18
DEF 14A
Definitive proxy
26 Jul 18
PRE 14A
Preliminary proxy
16 Jul 18
DEF 14A
Definitive proxy
10 Aug 17
DEFA14A
Additional proxy soliciting materials
27 Oct 16
DEFM14A
Proxy related to merger
26 Sep 16
PREM14A
Preliminary proxy related to merger
12 Sep 16
Other
EFFECT
Notice of effectiveness
7 Dec 20
CORRESP
Correspondence with SEC
1 Dec 20
UPLOAD
Letter from SEC
1 Dec 20
EFFECT
Notice of effectiveness
13 Apr 17
CORRESP
Correspondence with SEC
11 Apr 17
UPLOAD
Letter from SEC
9 Apr 17
UPLOAD
Letter from SEC
7 Apr 16
CORRESP
Correspondence with SEC
4 Apr 16
UPLOAD
Letter from SEC
31 Mar 16
EFFECT
Notice of effectiveness
7 Jan 14
Ownership
3
Microbot Medical / Simon Sharon ownership change
7 Apr 21
4
Microbot Medical / Harel Gadot ownership change
3 Feb 21
SC 13G
Microbot Medical / Chasing Value Asset Management ownership change
20 Jan 21
4
Microbot Medical / Prattipati Laxminarain ownership change
9 Nov 20
4
Microbot Medical / Scott R Burell ownership change
9 Nov 20
4
Microbot Medical / Yoseph Bornstein ownership change
9 Nov 20
4
Microbot Medical / Martin J. Madden ownership change
9 Nov 20
4/A
Microbot Medical / Yoseph Bornstein ownership change
21 Oct 20
4
Microbot Medical / Yoseph Bornstein ownership change
21 Oct 20
4
Microbot Medical / Yoseph Bornstein ownership change
13 Oct 20
Patents
APP
Utility
Self-cleaning Catheter Systems
18 Feb 21
Disclosed is a self-cleaning catheter system for fluid passage including a catheter, configured to be implanted in a body cavity of a subject and including at least one aperture fluidly coupling the catheter to the outside thereof, a cleaning unit configured for motion in the catheter such as to at least one of mechanically prevent, remove and mitigate occlusion in the at least one aperture, and an implantable controller.
APP
Utility
Self-cleaning Catheter Systems with Self-monitoring Capabilities
11 Feb 21
Disclosed is s self-cleaning catheter system with self-monitoring capabilities.
GRANT
Utility
Device for prevention of shunt stenosis
26 Jan 21
A method and a kit for the prevention of venous stenosis associated with the use of hemodialysis AV shunts.
APP
Utility
Implantable Catheter Assemblies
11 Nov 20
Disclosed is an implantable catheter for fluid passage, including a catheter tube, a catheter tip member including one or more apertures and an open proximal end, and a cleaning unit at least partially positioned within the catheter tip member.
Reddit threads
Daily Discussion Thread - June 11th, 2021
11 Jun 21
GI safe drugs are the future and Antibe Therapeutics leads the way (TSX: $ATE) (OTC: $ATBPF)
10 Jun 21
Daily Discussion Thread - June 10th, 2021
10 Jun 21
KemPharm ($KMPH) - THE SLEEPING GIANT
9 Jun 21
Daily Discussion Thread - June 9th, 2021
9 Jun 21
Daily Discussion Thread - June 8th, 2021
8 Jun 21
Daily Discussion Thread - June 4th, 2021
4 Jun 21
Daily Discussion Thread - June 3rd, 2021
3 Jun 21
Daily Discussion Thread - June 2nd, 2021
2 Jun 21
Daily Discussion Thread - June 1st, 2021
1 Jun 21